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David A. Rizzieri,1 Robert Storms,1 Dong-Feng Chen,2 Gwynn Long,1 Yiping Yang,1
Daniel A. Nikcevich,3 Cristina Gasparetto,1 Mitchell Horwitz,1 John Chute,1 Keith Sullivan,1
Therese Hennig,1 Debashish Misra,1 Christine Apple,1 Megan Baker,1 Ashley Morris,1
Patrick G. Green,1 Vic Hasselblad,4 Nelson J. Chao1Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk
of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte in-
fusions (DLIs) to 30 patients following a 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic
transplant. The primary endpoint of this study was feasibility and safety. Eight weeks following transplanta-
tion, donor NK cell-enriched DLIs were processed using a CD561 selecting column with up to 3 fresh in-
fusions allowed. Toxicity, relapse, and survival were monitored. T cell phenotype, NK cell functional
recovery, and KIR typing were assessed for association with outcomes. Fourteen matched and 16 mis-
matched transplanted patients received a total of 51 NK cell-enriched DLIs. Selection resulted in 96% (stan-
dard deviation [SD] 8%) purity and 83% (SD 21%) yield in the matched setting and 97% (SD 3%) purity and
77% (SD 24%) yield in the mismatched setting. The median number of CD32 CD561 NK cells infused was
10.6 (SD 7.91)  106 cells/kg and 9.21 (SD 5.6)  106 cells/kg, respectively. The median number of contam-
inating CD31CD562 T cells infused was .53 (1.1) 106 and .27 (.78) 106 in the matched and mismatched
setting, respectively. Only 1 patient each in the matched (n 5 14) or mismatched (n 5 16) setting experi-
enced severe aGVHD with little other toxicity attributable to the infusions. Long-term responders with mul-
tiple NK cell-enriched infusions and improved T cell phenotypic recovery had improved duration of
responses (p 5 .0045) and overall survival (OS) (P 5 .0058). A 1-step, high-yield process is feasible, and re-
sults in high doses of NK cells infused with little toxicity. NK cell-enriched DLIs result in improved immune
recovery and outcomes for some. Future studies must assess whether the improved outcomes are the
direct result of the high doses and improved NK cell function or other aspects of immune recovery.
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Nonmyeloablative (NMA) stem cell transplanta-
tion allows allogeneic immunotherapy to be offered
to older, more infirm patients with various types of
neoplastic diseases or bone marrow failure syndromes
with high rates of engraftment, low treatment-related
mortality (TRM), and high complete response rates;
however, long-term remission remain elusive [1-5].
Donor lymphocyte infusions (DLIs) have been
utilized to improve durability of response; however,
their use is limited by the risk of acute graft-versus-
host disease (aGVHD) and poor durability of response
[6-8]. Work by Vago et al. [9] indicates that 1 reason
for the poor response to DLIs may be that residual
leukemia cells following transplantation are altered1107
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effects, suggesting the importance of alternative mech-
anisms for tumor cell killing. Natural killer (NK) cells
may provide such benefit as they may mediate a graft-
versus-tumor (GVT) effect independently of aGVHD
[10,11]. However, the low frequency of NK cells in
adults (\10% of the DLI sample) has been posited
as 1 reason for relapse [9]. This study investigated
the safety and feasibility of infusing a DLI enriched
for NK cells to patients following a T cell-depleted,
NMA allogeneic transplant from a 3-6/6 human leuko-
cyte antigen (HLA) matched family member. Corol-
lary studies assessing the effect on T cell phenotype
and NK functional immune recovery and the impact
of KIR matching were also investigated.METHODS
Patients and Donors
Eligible adult patients were those who engrafted
following a fludarabine-based T cell-depleted NMA
allogeneic transplant regimen with alemtuzumab.
The details of this procedure have been previously
published [3]. Subsequent to transplantation, an infu-
sion of NK cell enriched DLIs was planned at 6 to 8
weeks. Donors were the same HLA 3-6/6 matched
family member used for the allogeneic transplantation.
Two more infusions could be provided at 8-week
intervals for up to 3 total infusions for those with
high-risk diseases (ie, high-risk cytogenetics or those
in second or greater remission). Adjustments in sched-
uling64 weeks were allowed for concerns over patient
health, disease status, or logistics of donor/lab avail-
ability for graft manipulation. Patients onmycopheno-
late at the initiation of the NK cell infusions for
planned prophylaxis continued until at least 2 weeks
following the first NK infusion, and then it was discon-
tinued. Patients with aGVHD had to be successfully
treated and on\30 mg/day of prednisone (or equiva-
lent) and equal to or greater than grade II aGVHD [12]
at the time of infusion of NK cells. Patients were eval-
uated weekly for toxicity following the NCI expanded
common toxicity criteria (version 3) [13] until a mini-
mum of 8 weeks following the last infusion, then at
least monthly for 3 additional months. Determination
of hematopoietic chimerism (by short tandem repeat
analysis) and immune reconstitution studies were
performed just prior to each NK cell infusion, and ev-
ery 3 months following the last NK cell infusion. All
patients signed informed consent for this institutional
review board (IRB)-approved protocol (Clinicaltrials.
gov # NCT 00586690).
NKCell-Enriched DLI Collection and Processing
Donor cells were collected with 1 apheresis proce-
dure without growth factors, selected forNK cells, andthen infused over 30 minutes fresh. Cell processing
was performed according to FACT procedures for col-
lection, labeling, and handling [14]. The lymphocytes
were enriched for NK cells using a CD56 antibody
(CliniMACS CD56 Reagent), CliniMACSplus instru-
ment using established company protocols (Miltenyi
Biotec Inc, Auburn, CA). Pre- and postprocessing
cell counts, cultures, and viability were assessed. To in-
fuse into patients, the product must have had a viability
$70% and Gram stain negative for signs of infection.
Patients received acetaminophen and diphenhydra-
mine premedication prior to each NK cell-enriched
DLI.
The goal for eachNK cell-enrichedDLI was to in-
fuse the most NK cells while maintaining a low risk of
aGVHD.We have previously shown the early infusion
of DLIs would have\20% chance of GVHD if the in-
fusate contained a maximum of 0.5  106 CD31 562
cells/kg patient weight in the 3-5/6 matched setting
and 1  106 CD31562 cells/kg patient weight in the
6/6 matched sibling setting [15]. Thus, the total dose
infused in this study was limited by ensuring the dose
of CD31562 cells did not exceed these limits. If mild
or moderate aGVHD occurred subsequent to the first
NK infusion, the patient was allowed to receive further
NK infusions only if the GVHD had resolved to meet
initial eligibility criteria.
T Cell Recovery
Using standard analyses for immunophenotypes,
these studies monitored the recovery of CD31 T cells
and CD561NK cells. Using multiparameter 3- and 4-
color FACS analysis, the CD31 T cells were further
described for their expression of CD4, CD8,
CD45RA, and CD45RO. Samples were tested 6 weeks
following transplantation and at 3-month intervals
from transplant through the first year and 6 month in-
tervals for the second.
NK Cell Functional Assays
As part of this report, we present a more ‘‘user-
friendly’’ flow-based assay for the assessment of NK
cell activity performed pre infusion, after 6 weeks,
and at subsequent 3-month intervals. K562 (ATCC;
# CCL-243) and Raji (ATCC; # CCL-86) cells were
exposed to varying ratios of effector peripheral blood
mononuclear cells (PBMC) prepared from 50-mL
blood collected from the patients. In each assay for
NK cell function, the total number of target cells was
held constant and 3-fold serial dilutions of the effector
cells, performed in triplicate, were established. The
percent lysis was measured on the target cells directly
as a percentage of 7AAD1 cells. Background (mini-
mum) 7AAD uptake was calculated from targets incu-
bated without effectors. The percent lysis was simply
calculated as: (% sample 7AAD uptake 2%minimum
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procedure and its validation are detailed in the
Supplemental Data section on-line. Positive and nega-
tive controls were run in tandem with all clinical sam-
ples. Samples not felt to be adequate or assays not
reliable when run in tandemwere discarded and not re-
ported in this data set. Data shown as ‘‘No’’ or ‘‘0’’ lysis
were from samples with a large blood specimen tested
with either too few lymphocytes to be active or those
present were not able to induce measurable lysis with
this assay.Statistical Analyses
This study evaluated the safety of NK cell enriched
DLIs using a CD561 selection technique and the im-
pact of infusions of high doses of such cells on recovery
of T cell and NK cell function. The primary clinical
endpoints included mortality, occurrence of severe
aGVHD or other unacceptable toxicity within 8 weeks
of the NK cell-enriched DLI, and duration of re-
sponse. Recognizing that aGVHD in the NMA setting
does not follow the traditional day 100 limit of onset,
we utilized the more conservative recommended ap-
proach to account for GVHD that clinically presents
similar to early aGVHD, even beyond the day 100 his-
torical cutoff, as aGVHD related to the procedure
[16]. Unacceptable toxicity was defined as equal to or
greater than grade III aGVHD of the gut or liver or
grade IV aGVHD of the skin lasting .7 days; other
grade 4 toxicity from the procedure in the major or-
gans that lasted .5 days; or TRM. The rate of unac-
ceptable toxicity was monitored with stopping rules
to permit the study to be closed early if there was evi-
dence that the true unacceptable toxicity rate was
$0.40. Although these infusions are provided early
following transplantation and severe toxicity could still
have occurred because of the primary transplant pro-
cedure, for this study any aGVHD or other toxicities
occurring after the first day of infusion of the NK
cell-enriched DLIs is here as study related.
Although this is a feasibility study, association with
laboratory measures of phenotypic T cell subset
recovery and NK cell function were undertaken to
investigate trends. For this investigation, CD31 lym-
phocyte recovery was arbitrarily assessed as ‘‘poor’’ if
there was enough sample for testing but too few lym-
phocytes to have a meaningful count on flow analysis
up to 25% the normal number, ‘‘moderate’’ with
.25% and \75% normal CD3 cell counts, and
‘‘good’’ if $75%. NK cell functional ability was cate-
gorized as ‘‘poor’’ for those with adequate sample for
testing but with\25% lysis, ‘‘midlevel’’ for 25% to
75% lysis, and ‘‘fully recovered’’ if$75% lysis was en-
countered in the in vitro assay. Correlation with clini-
cal outcomes was performed using a Cox proportional
hazards model while the effect on occurrence of equalto or greater than grade II aGVHD was measured
based on logistic regression analyses. Low-resolution
HLA- A, B , C, and high-resolution DRB1, DRB3/
4/5, and DQB1 were performed on each recipient
and related donor allowing assessment of the impact
of KIR compatibility with clinical outcomes.RESULTS
Fifty-one total NK cell-enriched DLIs were pro-
cessed and delivered to 30 consecutive patients. Four-
teen patients underwent a total of 24 infusions from 6/
6HLAmatched siblings, and 16 patients received a to-
tal of 27 infusions from mismatched family member (2
5/6 matched siblings, 14 3-4/6 matched family mem-
bers) from May of 2005 to the present. The first infu-
sion was a median of 2 months from transplant (range:
1.5-3), beyond the point at which the low concentra-
tion of persistent alemtuzumab is considered able to
induce lysis [17]. Six were on low doses of immune sup-
pression during the first infusion. All but 2 subjects had
donor engraftment accounting for .80% of their he-
matopoiesis at the time of first infusion.Cell Doses
In the matched setting, following the 1-step
enhancement with the CD561 selecting column
(Miltenyi Biotec, Inc, Auburn Ca), there was a median
CD561 cell purity of 96% (68%) (range: 87-100%)
and yield of 83% (standard deviation [SD] 21%) (range:
36%-88%) compared to the preprocessing number
(Table 1). The median dose of CD31561 cells/kg
infused was 1.94  106 (SD 2.22), and 10% of these
CD31/561 cells also expressed CD4 or 8 (data not
shown). The NK cells of interest, CD32561, were en-
riched with amedian infused dose of 10.60 (7.91) 106
cells/kg. The median CD31CD562 cells/kg dose,
most oftenCD4orCD81 cells concerning for their po-
tential to cause aGVHD,was assessed to ensure the risk
of aGVHDwas minimized with the intention to ‘‘cap’’
this dose at a maximum of 1 106 CD31CD562 cells/
kg infused. None of the infusions, in fact, reached this
‘‘cap’’ as a median of .53 (1.1)  106 CD31CD562
cells/kg was infused.
In the mismatched setting, following enhancement
with the CD561 selecting column, there was a median
CD561 cell purity of 97% (3%) (range: 86%-100%)
and yield of 77% (24%) (range: 36%-100%) (Table
1). The median dose of CD31561 cells/kg infused
was 3.67 (2.41)  106. The median dose of NK
CD32561 cells/kg infused was 9.21 (5.6)  106. The
median number of concerning CD31CD562 cells/kg
infused was 0.27 (0.78)  106 cells/kg. Remembering
the total cell dose of these contaminating CD31562
cells infused was capped to ensure #0.5  106, 6
Table 1. Cell Doses Infused Postprocessing
Donor Cell Dose (Standard Deviation) % Purity % Yield CD3+CD562/kg  105 CD3+CD56+/kg  106 CD32CD56+/kg  106
Matched Median (SD) 96 (8) 83 (21) .53 (1.1) 1.94 (2.22) 10.60 (7.91)
Mis Matched Median (SD) 97 (3) 77 (24) .27 (.78) 3.67 (2.41) 9.21 (5.56)
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for this reason.
Of the 14matched sibling recipients receiving a to-
tal of 24 NK cell-enriched DLIs, 8 received 1, 2 re-
ceived 2, and 4 patients received 3 infusions, the
maximum allowed in the study. Of those who received
\3 infusions, 4 were standard risk patients, 3 because
of mild aGVHD, 3 because of relapse of disease. The
16 recipients of mismatched grafts received a total of
27 NK cell enriched DLIs; 9 received 1, 3 received 2,
and 4 patients received 3 infusions. Of those who re-
ceived\3 infusions, 5 were not high-risk patients or
are still awaiting further infusions, 5 because of mild
aGVHD, and 1 because of relapse of disease.Toxicity
Mild skin aGVHD was experienced by 2 of the 14
matched patients prior to treatment on this study
(Table 2A). Six of these patients experienced equal to
or greater than grade 1 aGVHD, although only 1
had $3-4 (severe) overall aGVHD. The median onset
following the first NK cell infusion was 2 months
(range: 1-7 months). Mild skin aGVHD was experi-
enced by 4 of the 16 mismatched patients prior to en-
rollment in this study. At the doses provided, equal to
or greater than grade 1 aGVHD was experienced by 8
of the 16 patients, with skin GVHD being common,
although only 1 of the 16 had $3-4 overall aGVHD.
The median onset of aGVHD following the first NK
cell infusion was 1.5 months (range: 1-5 months).
Only 1 case of severe chronic GVHD (cGVHD) was
encountered.
Severe non-aGVHD toxicity was uncommon
(Table 2B). Only 1 subject in each group (matched
and mismatched) had bacterial sepsis, although viral
exanthemas remained a significant concern despite
the lymphocyte infusions with Polyoma, cytomalovi-
rus (CMV), vericella zoster virus (VZV), herpes sim-
ples virus (HSV), and Parainfluenza all encountered.
Three cases of cardiac dysrythmias (atrial) needing
medication for rate control were documented and 1
case of transient renal insufficiency. There was 1 case
of significant decrease in donor engraftment, possibly
leading to secondary graft failure, not because of
evident disease progression.
Durability of response
The 14 patients with a matched sibling donor have
a median follow-up of survivors of 12 months (range:3-33 months) and estimates of a 43% 1-year overall
survival (OS) with 8 in continuous remission. The 16
patients with a mismatched related family member do-
nor have a median follow-up of survivors of 27 months
(range: 3-45 months) and preliminary estimates reveal
a 42% 1-year OS, with 8 remaining alive and in remis-
sion.
Evaluating outcomes by disease type rather than
degree of graft match shows the 19 with a myeloid dis-
ease have a 50% 1-year survival and the 11 with a lym-
phoid disease had a 29% 1-year survival.Patient NK cell function and the impact of NK
cell-enriched DLIs
Figure 1 presents the results of the flow based assay
measuring NK cell function from a representative pa-
tient 2 to 6 months following transplant without the
NK cell-enriched DLI infusions provided in this se-
ries. There is minimal ability for recovering NK cells
to induce lysis for many months and even 6 months
later their function is only modest. This is the typical
pattern seen in our patients following this transplant
regimen. Functional analysis of NK activity before
and after the NK cell-enriched DLIs provided in this
study is represented in Figure 2. Although a few pa-
tients had measurable function just 6 weeks following
transplant and before the NK cell selected boost, this
represents a small fraction of the total with most sub-
jects having little measurable activity. In focusing on
the poor responders, subsequent NK cell-enriched
DLIs were associated with improved NK function in
4 of 7 tested patients (Figure 2C and D).
Association of lymphocyte phenotypic recovery
and NK functional ability
The majority of patients had poor lymphocyte
phenotypic recovery and NK cell functional ability
early in transplant recovery (6 weeks) prior to NK
cell enriched DLIs. Those with good early phenotypic
T cell recovery were most likely to be the same as those
with good NK cell functional ability (P 5 .005 using
Fisher’s mid P test).
In 10 patients with.1 infusion evaluated over time
for both phenotypic T cell recovery and NK cell func-
tional analysis performed, 70% (95% confidence inter-
val [CI] 5 35%-93%) had continued improvement in
T cell phenotypic recovery with at least 50% increase
in CD31 cell counts and 80% (95% CI 5 44%-98%)
improved their NK cell function.
Table 2. Toxicities for the Matched Sibling Donors, N5 14 (24 Total NK Cell-Enhanced Infusions); or Mismatched Family Member
Donors, N 5 16 (27 Total NK Cell-Enhanced Infusions)
(A) aGVHD
SiteY / Grade/
HLA Matched N 5 14 Patients; 24 Total Infusions HLA Mismatched N 5 16; 27 Total Infusions
1 2 3 4 1 2 3 4
Skin 1 1 2 — 3 3 1 —
Gut 2 — — — 2 — — 1
Liver — 1 — — 1 —
Overall 2 3 1 — 4 3 — 1
(B) Non-GVHD toxicity
Organ SystemY / CTC Grade/
Matched Mismatched
2 3 4 2 3 4/5
Cardiac-arrythmia 1 — — 2 — —
Renal Insufficiency — — — 1 — —
Infectious — — — —
Polyoma cystitis 1 1 — 2 —
CMV reactivation only 3 — — 6 — —
CMV disease — — — — 1 —
HSV — — 1 1 — —
Parainfluenza — 2 — — 3 —
VZV 1 — — — 1 —
Bacterial — 2 1 2 2 1
Parasitic (acanthamoeba) — — 1 — — —
Gastritis (non-GVHD) 2 — — — — —
Hemolytic anemia — — — 1 —
Pulmonary (noninfectious) 1 — — — —
Posttransplant lymphoproliferative
disorder (PTLD)
— — — — — 2
GVHD indicates graft-versus-host disease; VZV, varicella zoster virus; HSV, herpes simplex virus; CMV, cytomegalovirus; NK, natural killer.
One case of severe cGVHD noted in the mismatched group.
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and NK function with clinical outcomes
Long-term responders who had multiple NK
cell-enriched DLIs and improved T cell phenotypic re-
covery also had improved duration of remission asmea-
sured from day 1 posttransplant or day of first NK cell
enriched DLI (P 5 .0045 and .0133, respectively) and
better OSl (P 5 .0058). It remains undetermined if the
improved outcome is specific to the specific infusions,
NK cell function specifically, or the expected normal
kinetics of immune recovery in long-term responding
patients. There also was no statistical difference in
toxicities or survival endpoints using the ligand to ligand
model (ligand incompatibility), the receptor-ligand
model (missing ligand model), or donor activation of
KIR in this small study (data not shown).DISCUSSION
Our original report of NMA therapy with mis-
matched donors noted that, with the T cell-depleted
NMA transplant, the 2 most common causes of death
were infections and relapse with a 31% 1-year survival
in the mismatched setting [3]. Further, the value of
unselected DLIs remains questionable [15]. As themajority of spontaneous tumors are typically nonim-
munogenic, the elicitation of NK cell-mediated major
histocompatability complex unrestricted cytotoxicity
may be helpful in inducing significant antitumor
responses, whereas this cell type does not appear to
induce aGVHD [18-20].
Recent evidence has confirmed the phenotype of
the early recoveringNKcells is altered from the circulat-
ingNK cells seen in a normal host [3,21]. Further, Vago
et al. [22] have shown that it takes many months to have
meaningful NK cell activity following CD341 selected
haploidentical transplantation, and suggest the infusion
of alloreactive NK cells following transplant, similar
to the approach presented herein,might be an important
step forward. Recognizing these issues and the promise
ofNKcell mediated tumor lysis, infusions of autologous
or donorNK cells alone or in conjunction with cytokine
stimulation have been reported, although clinical benefit
in these settings remains limited [21,23-25]. These
and other prior efforts to exploit NK cells are often
costly, time consuming, and the benefit of attaining
a highly purified sample remains unclear. Our study
utilized a 1-step positive selection process, with a high
yield and CD561 purity similar to prior reports using
more stringent multistep NK cell manipulation
processes [26,27]. In addition, limiting infusions by
Figure 1. NK cell function was measured by their capacity to lyse K562
target cells, which is dependent upon the content of CD561 effector
cells within a sample. Improved NK cell ability to lyse the target cells
is denoted by a steeper line as effector-to-target cell ratios increase. Typ-
ical results following T cell-depleted nonmyeloablative therapy are
noted here. At 2 months following transplant in this patient there
were still not enough lymphocytes to quantify a meaningful response (in-
dicated with a stippled line). There was marginal recovery at approxi-
mately 4 months (black squares) and still only modest recovery at 6
months (shown with black triangles). Error bars represent the standard
deviation derived from triplicate samples.
Figure 2. Impact of NK cell-enriched DLI. (A) NK cell function was measure
fusions. At that time, NK cell function had returned fully in only a few patients
function (Mid). However, the majority of patients demonstrated low NK cell fun
tion (No, indicated with a stippled line). (B) The total recovery of lymphocytes t
weeks posttransplant, lymphocyte recovery was only consistently strong amo
NK cell donor lymphocyte infusion (DLI) was monitored in patients that had no
A). Of those patients, 4 responded within 6 to 8 weeks after a single NK cell DL
and third DLI. In all panels, the error bars represent the standard deviation der
patients with functional ability below the level of detection in this assay becau
measured with this assay.
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approximately a 2.5 log increase in NK cells infused,
compared with our prior work with unmanipulated
grafts, with no significant increase in aGVHD.
Using the flow-based assay, our data reveals that
few patients recover meaningful NK cell activity early
following transplantation, as recently reported in the
myeloablative setting as well [22]. Subsequent to infu-
sion of the NK-enriched DLIs, there was a notable in-
crease in T cell phenotypic recovery as well as NK cell
function in many patients, a reaction further enhanced
with continued infusions for many and associated with
a significant improvement in duration of response and
survival, suggesting a possible benefit from this ap-
proach. We are cognizant that this is simply an associ-
ation and not necessarily causal. It may simply be that
those who were healthier were more able to receive
further infusions because of not having toxicities and
remaining in remission.
As noted above, this study did not infuse solely pu-
rified NK cells as approximately 10% of the infusate
was CD31CD561 cells. Some of these cells are re-
ported to act as cytokine induced killer cells or
gamma-delta T cells, andmay also have a potent ability
to lyse tumor cells [28-30]. In addition, it has recently
been reported that NK cell function may directly
trigger antigen-specific T cell-mediated and humoral
responses, suggesting significant improvements in im-
mune activity may result from the interactions of NK
cells and other T cell subsets [31]. The NK cell func-
tional assay presented in this manuscript will be and at 6 to 8 weeks posttransplant, immediately prior to receiving NK in-
(Full), whereas 2 additional patients demonstrated at least some NK cell
ction (Low) or did not recover sufficient lymphocytes to assay NK func-
o the peripheral blood was examined within each patient group. At 6 to 8
ng patients that recovered full NK cell function (Full). (C) The impact of
t previously responded (‘‘Low’’ or ‘‘No’’ NK cell function patients in panel
I. (D) In 1 patient, NK cell function returned gradually following a second
ived from triplicate samples. *The ‘‘0’’ measure for percent lysis refers to
se of either poor function and/or too few cells recovered to have been
Biol Blood Marrow Transplant 16:1107-1114, 2010 1113NK Cell-Enriched DLIs Following Nonmyeloablative Transplantationimportant aspect of future studies that assess the causal
nature of the improved outcomes relating to general T
cell as well as specific NK cell function.
Dunbar et al. [32] have recently reported in the
HLA matched setting that those with low NK cell
levels 60 days following reduced intensity transplanta-
tion had higher relapse or death rates. Further, Pende
et al. [33] have shown the importance of NK cells as
clinical outcomes in haploidentical transplantation
was associated with NK cell activity regulated by a bal-
ance of activating and inhibiting KIRs, and Ruggeri
et al. [34] have reported that, in myelogenous patients
undergoing allogeneic transplant, using a donor with
NK alloreactive clones improved survival. These
studies reveal that NK cells clearly have an impact on
survival, although the mechanisms of action remain
unclear [35-38]. This feasibility study was not able to
determine the relevance of KIR typing in this
approach. Each of the 3 different models bear closer
examination in larger, comparative, studies evaluating
NK cell activity in relation to KIR activity before
donor selection can be based on this information.
This is the first such report to show that NK cells
can be significantly enriched using a 1-step processing
of DLIs and be safely infused in either the HLA
matched and mismatched setting early following
NMA allogeneic transplantation. Infusions had a low
risk of inducing severe aGVHD or other severe
toxicities. This supports future studies designed to
further improve outcomes via manipulation of NK
cell function. Importantly, this study does not provide
information as to whether the improved recovery or
outcome noted here specifically results from the
higher NK cell dose delivered, an issue that needs to
be addressed in future randomized trials.ACKNOWLEDGEMENTS
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